Nowadays, even though several biologic therapies are available to treat psoriasis, multidrug-resistant disease continues to be a therapeutic challenge. Combination therapy has therefore become increasingly important. In this context, apremilast, according to its safety profile, could easily be combined with biologics in patients with comorbidities and/or recalcitrant multidrug-resistant psoriasis.
Galluzzo, M., D'Adamio, S., Campione, E., Bianchi, L., Talamonti, M. (2018). Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy. MOLECULAR DIAGNOSIS & THERAPY [10.1007/s40291-018-0354-8].
Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy
Galluzzo, Marco;Campione, Elena;Bianchi, Luca;Talamonti, Marina
2018-08-03
Abstract
Nowadays, even though several biologic therapies are available to treat psoriasis, multidrug-resistant disease continues to be a therapeutic challenge. Combination therapy has therefore become increasingly important. In this context, apremilast, according to its safety profile, could easily be combined with biologics in patients with comorbidities and/or recalcitrant multidrug-resistant psoriasis.| File | Dimensione | Formato | |
|---|---|---|---|
|
Galluzzo- Treating a Multidrug Resistant Psoriatic HLAC18 Allele Carrier with Combination Ustekinumab Apremilast Therapy.pdf
solo utenti autorizzati
Licenza:
Copyright dell'editore
Dimensione
966.13 kB
Formato
Adobe PDF
|
966.13 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
